Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review

August C. Anderson; Joel Ho; Evan T. Hall; Raquibul Hannan; Jay J. Liao; Alexander V. Louie; Ting Martin Ma; Sarah P. Psutka; Ramesh Rengan; Shankar Siva; Anand Swaminath; Lisa Tachiki; Chad Tang; Bin Sing Teh; Joseph Tsai; Scott S. Tykodi; Emily Weg; Nicholas G. Zaorsky; Simon S. Lo

doi:10.1080/14796694.2024.2389769

Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review

August C. Anderson, Joel Ho, Evan T. Hall, Raquibul Hannan, Jay J. Liao, Alexander V. Louie, Ting Martin Ma, Sarah P. Psutka, Ramesh Rengan, Shankar Siva, Anand Swaminath, Lisa Tachiki, Chad Tang, Bin Sing Teh, Joseph Tsai, Scott S. Tykodi, Emily Weg, Nicholas G. Zaorsky, Simon S. Lo

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.

Original language	English (US)
Pages (from-to)	2573-2588
Number of pages	16
Journal	Future Oncology
Volume	20
Issue number	33
DOIs	https://doi.org/10.1080/14796694.2024.2389769
State	Published - 2024

Keywords

cytoreduction
immunotherapy
metastasis-directed therapy
oligometastatic
oligoprogressive
RCC
renal cell carcinoma
SABR
SBRT

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1080/14796694.2024.2389769

Cite this

Anderson, A. C., Ho, J., Hall, E. T., Hannan, R., Liao, J. J., Louie, A. V., Ma, T. M., Psutka, S. P., Rengan, R., Siva, S., Swaminath, A., Tachiki, L., Tang, C., Teh, B. S., Tsai, J., Tykodi, S. S., Weg, E., Zaorsky, N. G., & Lo, S. S. (2024). Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review. Future Oncology, 20(33), 2573-2588. https://doi.org/10.1080/14796694.2024.2389769

Anderson, AC, Ho, J, Hall, ET, Hannan, R, Liao, JJ, Louie, AV, Ma, TM, Psutka, SP, Rengan, R, Siva, S, Swaminath, A, Tachiki, L, Tang, C, Teh, BS, Tsai, J, Tykodi, SS, Weg, E, Zaorsky, NG & Lo, SS 2024, 'Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review', Future Oncology, vol. 20, no. 33, pp. 2573-2588. https://doi.org/10.1080/14796694.2024.2389769

@article{e2e865874d3d4316baedf591319672be,

title = "Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review",

abstract = "Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.",

keywords = "cytoreduction, immunotherapy, metastasis-directed therapy, oligometastatic, oligoprogressive, RCC, renal cell carcinoma, SABR, SBRT",

author = "Anderson, {August C.} and Joel Ho and Hall, {Evan T.} and Raquibul Hannan and Liao, {Jay J.} and Louie, {Alexander V.} and Ma, {Ting Martin} and Psutka, {Sarah P.} and Ramesh Rengan and Shankar Siva and Anand Swaminath and Lisa Tachiki and Chad Tang and Teh, {Bin Sing} and Joseph Tsai and Tykodi, {Scott S.} and Emily Weg and Zaorsky, {Nicholas G.} and Lo, {Simon S.}",

note = "Publisher Copyright: {\textcopyright} 2024 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2024",

doi = "10.1080/14796694.2024.2389769",

language = "English (US)",

volume = "20",

pages = "2573--2588",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "33",

}

TY - JOUR

T1 - Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma

T2 - a narrative review

AU - Anderson, August C.

AU - Ho, Joel

AU - Hall, Evan T.

AU - Hannan, Raquibul

AU - Liao, Jay J.

AU - Louie, Alexander V.

AU - Ma, Ting Martin

AU - Psutka, Sarah P.

AU - Rengan, Ramesh

AU - Siva, Shankar

AU - Swaminath, Anand

AU - Tachiki, Lisa

AU - Tang, Chad

AU - Teh, Bin Sing

AU - Tsai, Joseph

AU - Tykodi, Scott S.

AU - Weg, Emily

AU - Zaorsky, Nicholas G.

AU - Lo, Simon S.

PY - 2024

Y1 - 2024

N2 - Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.

AB - Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.

KW - cytoreduction

KW - immunotherapy

KW - metastasis-directed therapy

KW - oligometastatic

KW - oligoprogressive

KW - RCC

KW - renal cell carcinoma

KW - SABR

KW - SBRT

UR - http://www.scopus.com/inward/record.url?scp=85203528313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85203528313&partnerID=8YFLogxK

U2 - 10.1080/14796694.2024.2389769

DO - 10.1080/14796694.2024.2389769

M3 - Review article

C2 - 39258792

AN - SCOPUS:85203528313

SN - 1479-6694

VL - 20

SP - 2573

EP - 2588

JO - Future Oncology

JF - Future Oncology

IS - 33

ER -

Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this